Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 5/2016

01-05-2016 | MINI-Review

The role of leptin in diabetes: metabolic effects

Authors: Thomas H. Meek, Gregory J. Morton

Published in: Diabetologia | Issue 5/2016

Login to get access

Abstract

While it is well established that the adiposity hormone leptin plays a key role in the regulation of energy homeostasis, growing evidence suggests that leptin is also critical for glycaemic control. In this review we examine the role of the brain in the glucose-lowering actions of leptin and the potential mediators responsible for driving hyperglycaemia in states of uncontrolled insulin-deficient diabetes (uDM). These considerations highlight the possibility of targeting leptin-sensitive pathways as a therapeutic option for the treatment of diabetes. This review summarises a presentation given at the ‘Is leptin coming back?’ symposium at the 2015 annual meeting of the EASD. It is accompanied by two other reviews on topics from this symposium (by Christoffer Clemmensen and colleagues, DOI: 10.​1007/​s00125-016-3906-7, and by Gerald Shulman and colleagues, DOI: 10.​1007/​s00125-016-3909-4) and an overview by the Session Chair, Ulf Smith (DOI: 10.​1007/​s00125-016-3894-7).
Literature
1.
International Diabetes Federation (2013) IDF diabetes atlas, 6th edn. International Diabetes Federation, Brussels
2.
Chen L, Magliano DJ, Zimmet PZ (2011) The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nat Rev Endocrinol 8:228–236CrossRefPubMed
3.
Banting FG, Best CH (1990) Pancreatic extracts. 1922. J Lab Clin Med 115:254–272PubMed
4.
The DCCT Research Group (1988) Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care 11:567–573
5.
The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
6.
The Diabetes Control and Complications Trial Research Group (1997) Hypoglycemia in the diabetes control and complications trial. Diabetes 46:271–286CrossRef
7.
8.
Dubuc PU (1976) The development of obesity, hyperinsulinemia, and hyperglycemia in ob/ob mice. Metabolism 25:1567–1574CrossRefPubMed
9.
Wyse BM, Dulin WE (1970) The influence of age and dietary conditions on diabetes in the db mouse. Diabetologia 6:268–273CrossRefPubMed
10.
Pelleymounter MA, Cullen MJ, Baker MB et al (1995) Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269:540–543CrossRefPubMed
11.
Schwartz MW, Baskin DG, Bukowski TR et al (1996) Specificity of leptin action on elevated blood glucose levels and hypothalmic neuropeptide Y gene expression in ob/ob mice. Diabetes 45:531–535CrossRefPubMed
12.
Gavrilova O, Marcus-Samuels B, Leon LR, Vinson C, Reitman ML (2000) Leptin and diabetes in lipoatrophic mice. Nature 403:850, discussion 850–851PubMed
13.
Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL (1999) Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73–76CrossRefPubMed
14.
Petersen KF, Oral EA, Dufour S et al (2002) Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 109:1345–1350CrossRefPubMedPubMedCentral
15.
Patni N, Garg A (2015) Congenital generalized lipodystrophies—new insights into metabolic dysfunction. Nat Rev Endocrinol 11:522–534PubMed
16.
Chinookoswong N, Wang JL, Shi ZQ (1999) Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. Diabetes 48:1487–1492CrossRefPubMed
17.
Yu X, Park BH, Wang MY, Wang ZV, Unger RH (2008) Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci U S A 105:14070–14075CrossRefPubMedPubMedCentral
18.
Havel PJ, Uriu-Hare JY, Liu T et al (1998) Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: reversal by insulin. Am J Physiol 274:R1482–R1491PubMed
19.
Fujikawa T, Chuang JC, Sakata I, Ramadori G, Coppari R (2010) Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice. Proc Natl Acad Sci U S A 107:17391–17396CrossRefPubMedPubMedCentral
20.
German JP, Thaler JP, Wisse BE et al (2011) Leptin activates a novel CNS mechanism for insulin-independent normalization of severe diabetic hyperglycemia. Endocrinology 152:394–404CrossRefPubMedPubMedCentral
21.
Hidaka S, Yoshimatsu H, Kondou S et al (2002) Chronic central leptin infusion restores hyperglycemia independent of food intake and insulin level in streptozotocin-induced diabetic rats. FASEB J 16:509–518CrossRefPubMed
22.
Lin CY, Higginbotham DA, Judd RL, White BD (2002) Central leptin increases insulin sensitivity in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 282:E1084–E1091CrossRefPubMed
23.
24.
Ahima RS, Prabakaran D, Mantxoros C et al (1996) Role of leptin in the neuroendocrine response to fasting. Nature 382:250–252CrossRefPubMed
25.
26.
Dobbs R, Sakurai H, Sasaki H et al (1975) Glucagon: role in the hyperglycemia of diabetes mellitus. Science 187:544–547CrossRefPubMed
27.
28.
Gerich J, Davis J, Lorenzi M et al (1979) Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man. Am J Physiol 236:E380–E385PubMed
29.
30.
Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH (2011) Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60:391–397CrossRefPubMedPubMedCentral
31.
Lee Y, Berglund ED, Wang MY et al (2012) Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proc Natl Acad Sci U S A 109:14972–14976CrossRefPubMedPubMedCentral
32.
Strack AM, Sebastian RJ, Schwartz MW, Dallman MF (1995) Glucocorticoids and insulin: reciprocal signals for energy balance. Am J Physiol 268:R142–R149PubMed
33.
34.
Morton GJ, Meek TH, Matsen ME, Schwartz MW (2015) Evidence against hypothalamic–pituitary–adrenal axis suppression in the anti-diabetic action of leptin. J Clin Invest 125:4587–4591CrossRefPubMed
35.
Schwartz MW, Strack AM, Dallman MF (1997) Evidence that elevated plasma corticosterone levels are the cause of reduced hypothalamic corticotrophin-releasing hormone gene expression in diabetes. Regul Pept 72:105–112CrossRefPubMed
36.
37.
Omar BA, Andersen B, Hald J, Raun K, Nishimura E, Ahren B (2014) Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice. Diabetes 63:101–110CrossRefPubMed
38.
Gelling RW, Du XQ, Dichmann DS et al (2003) Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100:1438–1443CrossRefPubMedPubMedCentral
39.
Meek TH, Dorfman MD, Matsen ME et al (2015) Evidence that in uncontrolled diabetes, hyperglucagonemia is required for ketosis but not for increased hepatic glucose production or hyperglycemia. Diabetes 64:2376–2387CrossRefPubMed
40.
Cryer PE (2004) Diabetes mellitus: a fundamental and clinical text. Lippincott Williams & Wilkins, Philadelphia
41.
Rizza RA, Cryer PE, Gerich JE (1979) Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Investig 64:62–71CrossRefPubMedPubMedCentral
42.
Rosen SG, Clutter WE, Berk MA, Shah SD, Cryer PE (1984) Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man. J Clin Invest 73:405–411CrossRefPubMedPubMedCentral
43.
Elmquist JK, Bjorbaek C, Ahima RS, Flier JS, Saper CB (1998) Distributions of leptin receptor mRNA isoforms in the rat brain. J Comp Neurol 395:535–547CrossRefPubMed
44.
Munzberg H, Flier JS, Bjorbaek C (2004) Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. Endocrinology 145:4880–4889CrossRefPubMed
45.
Haque MS, Minokoshi Y, Hamai M, Iwai M, Horiuchi M, Shimazu T (1999) Role of the sympathetic nervous system and insulin in enhancing glucose uptake in peripheral tissues after intrahypothalamic injection of leptin in rats. Diabetes 48:1706–1712CrossRefPubMed
46.
Minokoshi Y, Haque MS, Shimazu T (1999) Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats. Diabetes 48:287–291CrossRefPubMed
47.
Bingham NC, Anderson KK, Reuter AL, Stallings NR, Parker KL (2008) Selective loss of leptin receptors in the ventromedial hypothalamic nucleus results in increased adiposity and a metabolic syndrome. Endocrinology 149:2138–2148CrossRefPubMedPubMedCentral
48.
Dhillon H, Zigman JM, Ye C et al (2006) Leptin directly activates SF1 neurons in the VMH, and this action by leptin is required for normal body-weight homeostasis. Neuron 49:191–203CrossRefPubMed
49.
Nonogaki K, Iguchi A (1997) Role of central neural mechanisms in the regulation of hepatic glucose metabolism. Life Sci 60:797–807CrossRefPubMed
50.
Meek TH, Matsen ME, Dorfman MD et al (2013) Leptin action in the ventromedial hypothalamic nucleus is sufficient, but not necessary, to normalize diabetic hyperglycemia. Endocrinology 154:3067–3076CrossRefPubMedPubMedCentral
51.
da Silva AA, do Carmo JM, Freeman JN, Tallam LS, Hall JE (2009) A functional melanocortin system may be required for chronic CNS-mediated antidiabetic and cardiovascular actions of leptin. Diabetes 58:1749–1756CrossRefPubMedPubMedCentral
52.
Meek TH, Matsen ME, Damian V, Cubelo A, Chua SC Jr, Morton GJ (2014) Role of melanocortin signaling in neuroendocrine and metabolic actions of leptin in male rats with uncontrolled diabetes. Endocrinology 155:4157–4167CrossRefPubMedPubMedCentral
53.
Fujikawa T, Berglund ED, Patel VR et al (2013) Leptin engages a hypothalamic neurocircuitry to permit survival in the absence of insulin. Cell Metab 18:431–444CrossRefPubMedPubMedCentral
54.
Flak JN, Patterson CM, Garfield AS et al (2014) Leptin-inhibited PBN neurons enhance responses to hypoglycemia in negative energy balance. Nat Neurosci 17:1744–1750CrossRefPubMedPubMedCentral
55.
Garfield AS, Shah BP, Madara JC et al (2014) A parabrachial-hypothalamic cholecystokinin neurocircuit controls counterregulatory responses to hypoglycemia. Cell Metab 20:1030–1037CrossRefPubMedPubMedCentral
56.
57.
Aponte Y, Atasoy D, Sternson SM (2011) AGRP neurons are sufficient to orchestrate feeding behavior rapidly and without training. Nat Neurosci 14:351–355CrossRefPubMedPubMedCentral
58.
59.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432CrossRefPubMed
60.
Farr OM, Gavrieli A, Mantzoros CS (2015) Leptin applications in 2015: what have we learned about leptin and obesity? Curr Opin Endocrinol Diabetes Obes 22:353–359CrossRefPubMed
61.
Cummings BP, Bettaieb A, Graham JL et al (2011) Subcutaneous administration of leptin normalizes fasting plasma glucose in obese type 2 diabetic UCD-T2DM rats. Proc Natl Acad Sci U S A 108:14670–14675CrossRefPubMedPubMedCentral
Metadata
Title
The role of leptin in diabetes: metabolic effects
Authors
Thomas H. Meek
Gregory J. Morton
Publication date
01-05-2016
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 5/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-3898-3

Other articles of this Issue 5/2016

Diabetologia 5/2016 Go to the issue

Review

Microbial transmission from mothers with obesity or diabetes to infants: an innovative opportunity to interrupt a vicious cycle

Short Communication

The anterior chamber of the eye is a transplantation site that supports and enables visualisation of beta cell development in mice

Commentary

Bariatric surgery: traversing the CROSSROADS into mainstream diabetes care

Article

Incidence of register-based diabetes 10 years after a stepwise diabetes screening programme: the ADDITION-Denmark study

Article

GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial

Article

Decoration of intramyocellular lipid droplets with PLIN5 modulates fasting-induced insulin resistance and lipotoxicity in humans

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits